Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CHEK-ATP082 | Human | HEK293/Human TrkB Stable Cell Line | |||
NT2-H5228 | Human | Human TrkB / NTRK2 Protein, His Tag | ![]() |
![]() ![]() |
|
NT2-H5254 | Human | Human TrkB / NTRK2 Protein, Fc Tag | ![]() |
![]() ![]() |
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Entrectinib | NMS-E628; RXDX-101; RG-6268 | Approved | Nerviano Medical Sciences Srl | Rozlytrek, 罗圣全 | Mainland China | Solid tumours | Roche (China) Holding Ltd | 2019-06-18 | Breast Neoplasms; Thyroid Cancer, Papillary; Melanoma; Carcinoma, Non-Small-Cell Lung; Lymphoma, Large-Cell, Anaplastic; Leukemia, Myeloid, Acute; Hepatic Insufficiency; Colorectal Neoplasms; Brain Neoplasms; Sarcoma; Cholangiocarcinoma; Solid tumours; Central Nervous System Neoplasms; Neuroendocrine Tumors; Salivary Gland Neoplasms; Pancreatic Neoplasms; Neoplasms; Carcinoma, Renal Cell; Head and Neck Neoplasms; Ovarian Neoplasms; Skin Melanoma | Details |
Cabozantinib S-malate | XL-184; BMS-907351 | Approved | Exelixis Inc | Cometriq, Cabometyx | Japan | Carcinoma, Renal Cell | Takeda | 2012-11-29 | Osteosarcoma; Thyroid Neoplasms; Gliosarcoma; Colorectal Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Hepatic Insufficiency; Astrocytoma; Breast Neoplasms; Sarcoma, Ewing; Lymphoma; Carcinoma, Adenosquamous; Adenocarcinoma, Clear Cell; Sarcoma, Clear Cell; Medullary thyroid cancer (MTC); Cholangiocarcinoma; Prostatic Neoplasms; Neurofibroma, Plexiform; Urethral Neoplasms; Carcinoma, Neuroendocrine; Meningioma; Carcinoma, Non-Small-Cell Lung; Paraganglioma; Melanoma; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Adenocarcinoma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Neuroblastoma; Glioma; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Endometrial Neoplasms; Lung Neoplasms; Sarcoma, Alveolar Soft Part; Uterine Neoplasms; Fallopian Tube Neoplasms; Carcinoid Tumor; Neurofibromatoses; Seminoma; Carcinoma, Transitional Cell; Glioblastoma; Rejection of liver transplantation; Carcinoma, Merkel Cell; Hepatoblastoma; Pain; Pheochromocytoma; Neoplasms; Carcinoma, Renal Cell; B | Details |
Larotrectinib sulfate | LOXO-101; ARRY-470; BAY-2757556 | Approved | Array Biopharma | Vitrakvi, 维泰凯 | Mainland China | Solid tumours | Bayer Healthcare Company Ltd | 2018-11-26 | Endometrial Neoplasms; Sarcoma, Ewing; Neuroblastoma; Sarcoma; Histiocytosis, Langerhans-Cell; Breast Neoplasms; Cholangiocarcinoma; Prostatic Neoplasms; Histiocytic Sarcoma; Colorectal Neoplasms; Neoplasms, Neuroepithelial; Lung Neoplasms; Uterine Neoplasms; Osteosarcoma; Lymphoma; Lymphoma, Non-Hodgkin; Glioma; Carcinoma, Squamous Cell; Thyroid Neoplasms; Esophageal adenocarcinoma; Melanoma; Neoplasms, Germ Cell and Embryonal; Xanthogranuloma, Juvenile; Uterine Cervical Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Rectal Neoplasms; Fibrosarcoma; Rhabdomyosarcoma; Liver Neoplasms; Leukemia; Ovarian Neoplasms; Medulloblastoma; Solid tumours; Hepatoblastoma; Rhabdoid Tumor; Carcinoma, Renal Cell; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Ependymoma; Stomach Neoplasms; Skin Neoplasms; Wilms Tumor; Carcinoma, Transitional Cell; Colonic Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Central Nervous System Neoplasms; Urinary Bladder Neoplasms; Multiple | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
ACD-856 | ACD-856 | Alzecure Pharma Ab | Details | ||
Lestaurtinib | SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 | Phase 3 Clinical | Kyowa Hakko Kirin Co Ltd | Leukemia; Leukemia, Myeloid; Bone Marrow Neoplasms; Polycythemia Vera; Neuroblastoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Psoriasis; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thrombocythemia, Essential | Details |
HG-030 | HG-030 | Phase 1 Clinical | Hitgen Inc | Solid tumours | Details |
This web search service is supported by Google Inc.